Generic Drug Bioequivalence Testing Details Emerge In China
This article was originally published in PharmAsia News
Executive Summary
Bioequivalence testing is sure to have a profound effect on pricing, bidding and reimbursement, Chinese pharmaceutical industry players say. Now draft guidelines shed light on SFDA’s thinking on the issue.